Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • A Secular Growth Story Emerging in Radiopharmaceuticals

    From targeted cancer therapies to Alzheimer’s imaging, radiopharma is scaling fast across medicine.

    Read more

  • Smart Wealth Planning Tips for Each Stage of Your Career: Early Career Professionals

    Managing your budget and credit, saving and investing, and understanding your company benefits are critical to building a sound financial future.

    Watch the video

  • Smart Wealth Planning Tips for Each Stage of Your Career: Mid-Career Professionals

    Take full advantage of retirement savings vehicles during this phase of your career while you are juggling expenses and building wealth.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures